WEKO3
アイテム
{"_buckets": {"deposit": "ef323dbe-25f5-47ea-bb01-a2dc7f70bda3"}, "_deposit": {"id": "49384", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "49384"}, "status": "published"}, "_oai": {"id": "oai:tsukuba.repo.nii.ac.jp:00049384", "sets": ["919", "5928", "7313"]}, "item_5_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "109", "bibliographicPageStart": "105", "bibliographicVolumeNumber": "30", "bibliographic_titles": [{}, {"bibliographic_title": "Anti-Cancer Drugs", "bibliographic_titleLang": "en"}]}]}, "item_5_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Lung cancer is a major health concern worldwide, but new immunotherapeutic treatments for lung cancer have shown great promise and the prognosis for many severe cancers including lung cancer has been improving. In May 2017, the Food and Drug Administration approved pembrolizumab, a therapeutic antibody that blocks lymphocytic programmed death-1 (PD-1), as a first-line treatment for any solid tumor with specific genetic features. Pembrolizumab is a therapeutic antibody that blocks lymphocytic PD-1, the ligand of which (PD-L1) is expressed on tumor cells and which can prevent the immune system from recognizing and destroying tumors. Here, we report two cases of double cancer (case 1: lung and bladder cancer; case 2: gastric and lung cancer) in which pembrolizumab was effective for the treatment of both cancers in each patient.", "subitem_description_type": "Abstract"}]}, "item_5_publisher_27": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Lippincott, Williams \u0026 Wilkins"}]}, "item_5_relation_10": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "30074503", "subitem_relation_type_select": "PMID"}}]}, "item_5_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1097/CAD.0000000000000677", "subitem_relation_type_select": "DOI"}}]}, "item_5_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2019 Wolters Kluwer Health, Inc. All rights reserved."}]}, "item_5_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_5_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0959-4973", "subitem_source_identifier_type": "ISSN"}]}, "item_5_source_id_9": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA10850925", "subitem_source_identifier_type": "NCID"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "山田, 英恵"}, {"creatorName": "ヤマダ, ヒデヤス", "creatorNameLang": "ja-Kana"}, {"creatorName": "YAMADA, Hideyasu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "165940", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "70779587", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000070779587"}, {"nameIdentifier": "0000003888", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000003888"}]}, {"creatorNames": [{"creatorName": "佐藤, 浩昭"}, {"creatorName": "サトウ, ヒロアキ", "creatorNameLang": "ja-Kana"}, {"creatorName": "SATOH, Hiroaki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "347", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "00261800", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000000261800"}, {"nameIdentifier": "0000001747", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000001747"}]}, {"creatorNames": [{"creatorName": "Hida, Norihito", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "207078", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamagishi, Tetsuya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "207079", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hiroshima, Yoshinori", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "207080", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshii, Shinichi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "207081", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saito, Takefumi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "207082", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hizawa, Nobuyuki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "207083", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-01-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "ACD_30.pdf", "filesize": [{"value": "251.8 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 251800.0, "url": {"label": "ACD_30", "url": "https://tsukuba.repo.nii.ac.jp/record/49384/files/ACD_30.pdf"}, "version_id": "9e51de40-ca2a-4785-9f68-a4e1198e7f0d"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer"}]}, "item_type_id": "5", "owner": "1", "path": ["919", "5928", "7313"], "permalink_uri": "http://hdl.handle.net/2241/00154854", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-03-19"}, "publish_date": "2019-03-19", "publish_status": "0", "recid": "49384", "relation": {}, "relation_version_is_last": true, "title": ["Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer"], "weko_shared_id": 5}
Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer
http://hdl.handle.net/2241/00154854
http://hdl.handle.net/2241/001548548b378695-4ef6-4bd4-a74e-2fa946f4f527
名前 / ファイル | ライセンス | アクション |
---|---|---|
ACD_30 (251.8 kB)
|
|
Item type | Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-03-19 | |||||
タイトル | ||||||
タイトル | Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | journal article | |||||
著者 |
山田, 英恵
× 山田, 英恵× 佐藤, 浩昭× Hida, Norihito× Yamagishi, Tetsuya× Hiroshima, Yoshinori× Yoshii, Shinichi× Saito, Takefumi× Hizawa, Nobuyuki |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Lung cancer is a major health concern worldwide, but new immunotherapeutic treatments for lung cancer have shown great promise and the prognosis for many severe cancers including lung cancer has been improving. In May 2017, the Food and Drug Administration approved pembrolizumab, a therapeutic antibody that blocks lymphocytic programmed death-1 (PD-1), as a first-line treatment for any solid tumor with specific genetic features. Pembrolizumab is a therapeutic antibody that blocks lymphocytic PD-1, the ligand of which (PD-L1) is expressed on tumor cells and which can prevent the immune system from recognizing and destroying tumors. Here, we report two cases of double cancer (case 1: lung and bladder cancer; case 2: gastric and lung cancer) in which pembrolizumab was effective for the treatment of both cancers in each patient. | |||||
書誌情報 |
en : Anti-Cancer Drugs 巻 30, 号 1, p. 105-109, 発行日 2019-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0959-4973 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA10850925 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 30074503 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1097/CAD.0000000000000677 | |||||
権利 | ||||||
権利情報 | © 2019 Wolters Kluwer Health, Inc. All rights reserved. | |||||
著者版フラグ | ||||||
値 | author | |||||
出版者 | ||||||
出版者 | Lippincott, Williams & Wilkins |